Anti-Infective Drug News

BMI View: A number of developments within the European hepatitis C market indicate that the drug pricing battle seen in the US is extending to Europe. European payers have already secured substantial discounts for existing HCV drugs, yet current cost-containment trends in Europe mean that competitive pricing leading to further discounts is welcomed by European payers.

Table of Contents

• US HCV Drug Pricing Battle To Extend To Europe Antibacterials
• Agreements
• Roche/Meiji/Fedora Enter Collaboration For Development Of OP0595
• Valneva To Acquire Dukoral Vaccine From Crucell
• SinSa Signs Deal For Technology Platform To Prevent Antibiotic Resistance
• R&D
• Aradigm Granted Key Composition Of Matter Patents For Pulmaquin In Europe/Australia
• Galapagos Secures IWT Grant For Antibiotic Research Antifungals
• Product Updates
• FDA Advisory Committee Recommends Cresemba Approval For Invasive Aspergillosis/Mucormycosis
• R&D
• Scynexis' SCY-078 Oral Formulation Gains FDA Fast Track Designation Antivirals
• Agreements
• Debiopharm Regains Full Rights To Alisporivir Programme
• Vical/AnGes Collaborate To Develop Therapy Against Ebola
• Product Updates
• Prevenar 13 Gains CHMP Positive Opinion For Vaccine-Type Pneumococcal Pneumonia In Adults
• AbbVie's Viekirax/Exviera Licensed For Use In UK For cHCV
• Payer Pressure Forces Gilead/AbbVie Drug Pricing Battle To Remain Heated
• Mylan Launches Lamivudine In US
• Health Canada Approves Novartis' Fluad Pediatric Flu Vaccine
• Gilead Likely To Weather The Indian Sofosbuvir Patent Rejection Storm
• R&D
• Chimerix Granted US Patent Allowance Covering Brincidofovir
• Waning Of Ebola Outbreak Could Hamper Vaccine Developments
• J&J Forms Ebola Vaccine Development Consortia; Secures Funding Corporate Activity
• Tekmira/OnCore Merge To Create Global HBV Company
• Merck Completes Tender Offer To Acquire Cubist
• Court Orders SIGA To Pay Tecovirimat Damages To PharmAthene
• Moderna Launches New Venture Valera For Infectious Diseases
• NovaBiotics Raises Funds Via Private Placement